Skip to main content
Premium Trial:

Request an Annual Quote

GeneNews Reports Loss of $1.3M in Q1

NEW YORK (GenomeWeb News) – Molecular Diagnostics firm GeneNews today said that its first-quarter loss was C$1.3 million (US$1.3 million), or C$.01 per share.

Results for the three months ended March 31 compare to a net loss of C$1.1 million, or C$.02 per share, a year ago.

The Toronto-based company did not disclose other financial information for the quarter, and its quarterly financial filing was not yet available on the SEDAR website, which provides public securities documents for Canadian companies.

In mid-April, GeneNews announced a rights offering intended to raise more than C$2.5 million in gross proceeds to go toward commercialization of its ColonSentry, a blood-based colon cancer risk stratification test, and for general corporate and administrative expenses. The test was launched last month in the US by GeneNews' marketing partner Enzo Clinical Labs.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.